Losartan and diabetic nephropathy: commentaries on the RENAAL study

Fisman, Enrique Z.; Tenenbaum, Alexander; Motro, Michael
January 2002
Cardiovascular Diabetology;2002, Vol. 1, p2
Academic Journal
The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study is a multinational, double-blind, randomized, placebo controlled trial which was recently published. It was aimed to evaluate the effect of the angiotensin receptor blocker losartan in patients with diabetic nephropathy. The primary efficacy measure was the time to the first event of the composite end point of a doubling of serum creatinine, end-stage renal disease, or death. The conclusion was that losartan led to significant improvement in renal outcomes, that was beyond that attributable to blood pressure control in patients with type 2 diabetes and nephropathy. The perusal of the report raises concern, regarding to both the patient population as well as the outcome measures. At randomization, the placebo group included more patients with angina, myocardial infarction and lipid disorders than the losartan group. Information on glucose metabolism was disregarded, and data on antihyperglycemic therapy � which may have undesirable influences on cardiac performance � were not included in a multivariate analysis. In addition, only data on first hospitalization were reported, whilst information on total specific-cause hospitalizations was disregarded, thus potentially masking further unfavorable events. Furthermore, creatinine seems not to be a reliable surrogate end point. Based on its mechanism of action, losartan may possess favorable renoprotective properties. However, due to the methodological flaws and the incomplete data in the RENAAL study, the question of the effectiveness and safety of this drug in diabetic nephropathy remains yet unanswered.


Related Articles

  • Identification of the Stages of Diabetic Nephropathy at Which Angiotensin II Receptor Blockers Most Effectively Suppress Albuminuria. Ogawa, Susumu; Matsushima, Masato; Mori, Takefumi; Okamura, Masashi; Senda, Miho; Sakamoto, Takuya; Nako, Kazuhiro; Ito, Sadayoshi // American Journal of Hypertension;Sep2013, Vol. 26 Issue 9, p1064 

    BACKGROUND It is unclear when angiotensin II receptor blockers (ARBs) produce their strongest antialbuminuric effect (AAE) in patients with diabetic nephropathy. ARBs produce stronger AAEs when urinary excretion of reactive oxygen species (ROS) and/or of angiotensinogen (AGT) is higher before...

  • Effect of Periodontitis on Overt Nephropathy and End-Stage Renal Disease in Type 2 Diabetes. Shultis, Wendy A.; Weil, E. Jennifer; Looker, Helen C.; Curtis, Jeffrey M.; Shlossman, Marc; Genco, Robert J.; Knowler, William C.; Nelson, Robert G. // Diabetes Care;Feb2007, Vol. 30 Issue 2, p306 

    OBJECTIVE -- The purpose of this study was to investigate the effect of periodontitis on development of overt nephropathy, defined as macroalbuminuria, and end-stage renal disease (ESRD) in type 2 diabetes. RESEARCH DESIGN AND METHODS -- Individuals residing in the Gila River Indian Community...

  • Evaluation of Renal Disorders in Type 2 Diabetic Patients Using Ultrsonography. Jastaniah, Saddig D.; Alsayed, Naglaa M.; Awad, Ibrahim A.; Fida, Hashim R.; Elniel, Hammad H. // Open Journal of Medical Imaging;Dec2013, Vol. 3 Issue 4, p165 

    Type 2 diabetes mellitus (type 2 DM) is one of the common epidemics worldwide. The prevalence of type 2 DM is high among Saudi population. Renal affection by DM is in the form of nephropathy that may end in the end stage of renal disease (ESRD) and renal failure warrants chronic dialysis or...

  • VIKOR Method for Diabetic Nephropathy Risk Factors Analysis. BONDOR, Cosmina-Ioana; KACSO, Ina Maria; LENGHEL, Alina; ISTRATE, Dan; MUREŞAN, Adriana // Applied Medical Informatics;Jan2013, Vol. 32 Issue 1, p43 

    Diabetic kidney disease is an important complication of type 2 diabetes mellitus (T2DM) and has an economic impact in growth due to the increasing prevalence of T2DM. Identification of diabetic kidney disease risk factors is a priority for both the patient and the healthcare system. The aim of...

  • Progression of nephropathy in type 2 diabetic patients. Rossing, Kasper; Christensen, Per K.; Hovind, Peter; Tarnow, Lise; Rossing, Peter; Parving, Hans-Henrik // Kidney International;Oct2004, Vol. 66 Issue 4, p1596 

    Progression of nephropathy in type 2 diabetic patients.Background.Nephropathy in type 2 diabetes is the single most common cause of end-stage renal disease (ESRD), but the decline in kidney function varies considerably between individuals, and determinants of renal function loss, early in the...

  • C REACTIVE PROTEIN IN DIABETES MELLITUS TYPE 2 COMPLICATED WITH DIABETIC NEPHROPATHY. Matei, D.; Moldovan, C.; Muresan, M.; Micle, L.; Micle, O.; Burta, O.; Oros, R.; Muresan, A. // Fiziologia - Physiology;2010, Vol. 20 Issue 2, p15 

    Aims: In subjects with diabetes mellitus type 2 complicated with diabetic nephropathy, there is an increase of markers of inflammation, generated by multiple mechanisms. Chronical subclinical inflammation is a finding observed in diabetes mellitus type 2. This study was designed to establish the...

  • How Reliable Is Estimation of Glomerular Filtration Rate at Diagnosis of Type 2 Diabetes? Chudleigh, Richard A.; Dunseath, Gareth; Evans, William; Harvey, John N.; Evans, Philip; Ollerton, Richard; Owens, David R. // Diabetes Care;Feb2007, Vol. 30 Issue 2, p300 

    OBJECTIVE -- The Cockcroft-Gault (CG) and Modification of Diet in Renal Disease (MDRD) equations previously have been recommended to estimate glomerular filtration rate (GFR). We compared both estimates with true GFR, measured by the isotopic 51Cr-EDTA method, in newly diagnosed,...

  • Dual therapy of rosiglitazone/pioglitazone with glimepiride on diabetic nephropathy in experimentally induced type 2 diabetes rats. Rao, Ravi Prakash; Singh, Ansima; Jain, Arun K; Srinivasan, Bhartu Parsharthi // Journal of Biomedical Research;Nov2011, Vol. 25 Issue 6, p411 

    Abstract: Diabetic nephropathy is a major cause of end-stage renal disease (ESRD) in the general population. It is estimated that diabetic nephropathy will eventually develop in about 40% of all patients with diabetes; therefore, prevention is critical for delaying the development and...

  • Prevalence & Risk Factors of Nephropathy in Type 2 Diabetic Patients. Vimalkumar, V. K.; Anand Moses, C. R.; Padmanaban, S. // International Journal of Collaborative Research on Internal Medi;Aug2011, Vol. 3 Issue 8, p598 

    Background: 31.7 million people in India are suffering from diabetes. Diabetic nephropathy (Kimmelstiel-Wilson syndrome) is the leading cause of end-stage renal disease (ESRD) worldwide and a leading cause of DM-related morbidity and mortality. It is estimated that 79.4 million diabetic patients...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics